Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
OSH Oak Street Health Inc
LESL Leslie's Inc
AAPL Apple Inc
BYM BlackRock Municipal Income Quality Trust
DLA Delta Apparel Inc
PEG Public Service Enterprise Group Inc
WBD Warner Bros Discovery Inc
ERO Ero Copper Corp
ZIM ZIM Integrated Shipping Services Ltd
Go

Health Care : Biotechnology | Small Cap Value

Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.

Closing Price: $2.71

Day's Change: -0.06 (-2.17%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.80

Day's Low: 2.70

Volume (Light) Volume: 14,503 10-day average volume: 23,485: 14,503

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.